The FDA has approved lurbinectedin plus atezolizumab for maintenance therapy in extensive-stage small cell lung cancer after induction therapy. This combination has been specifically approved for first-line maintenance therapy in this patient population. The approval is seen as an advance in the care of small cell lung cancer, with potential implications for future treatment developments.